Markus Ries
Ries, Markus 1971-
VIAF ID: 306330891 (Personal)
Permalink: http://viaf.org/viaf/306330891
Preferred Forms
- 100 0 _ ‡a Markus Ries
- 100 1 _ ‡a Ries, Markus ‡d 1971-
4xx's: Alternate Name Forms (2)
5xx's: Related Names (3)
- 551 _ _ ‡a Bad Hersfeld ‡4 ortw ‡4 https://d-nb.info/standards/elementset/gnd#placeOfActivity
- 551 _ _ ‡a Heidelberg ‡4 ortw ‡4 https://d-nb.info/standards/elementset/gnd#placeOfActivity
- 510 2 _ ‡a Klinikum Heidelberg ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
Works
Title | Sources |
---|---|
Angiokeratoma and pain, but not Fabry's disease: considerations for differential diagnosis | |
Apoptotic abnormalities in differential gene expression in peripheral blood mononuclear cells from children with Fabry disease. | |
An Assessment of Publication Status of Pediatric Liver Transplantation Studies | |
Biochemical markers of lipid storage and vasculopathy in Fabry disease | |
Cardiac involvement in Anderson-Fabry disease. | |
Challenging behavior in mucopolysaccharidoses types I-III and day-to-day coping strategies: a cross sectional explorative study | |
Cognitive and Behavioral Consequences of Pediatric Delirium: A Pilot Study | |
Critical appraisal of genotype assessment in molybdenum cofactor deficiency. | |
Critical assessment of chitotriosidase analysis in the rational laboratory diagnosis of children with Gaucher disease and Niemann-Pick disease type A/B and C | |
Cross-sectional analysis on publication status and age representation of clinical studies addressing mechanical ventilation and ventilator-induced lung injury in infants and children | |
Decision-making in acute viral bronchiolitis: A universal guideline and a publication gap | |
Disasters in Germany and France: An Analysis of the Emergency Events Database From a Pediatric Perspective | |
Disease awareness or subtle product placement? Orphan diseases featured in the television series "House, M.D." - a cross-sectional analysis | |
drug development pipeline for glioblastoma: a cross sectional assessment of the FDA orphan drug product designation database | |
The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. | |
Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents. | |
Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016). | |
Enzyme replacement therapy in orphan and ultra-orphan diseases: the limitations of standard economic metrics as exemplified by Fabry-Anderson disease. | |
Fabry Disease: A Disorder of Childhood Onset | |
Fabry's disease--an important risk factor for stroke. | |
Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease | |
Intuitive Global Insight Into COVID-19 Clinical Research Activities-The "COVID-19 Map of Hope" | |
Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting | |
The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. | |
Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease. | |
Neurological manifestation of Fabry disease in females | |
Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease | |
De novo variants in CELF2 that disrupt the nuclear localization signal cause developmental and epileptic encephalopathy | |
Parapelvic kidney cysts: a distinguishing feature with high prevalence in Fabry disease. | |
Pressure for drug development in lysosomal storage disorders – a quantitative analysis thirty years beyond the US orphan drug act | |
A prospective 10-year study of individualized, intensified enzyme replacement therapy in advanced Fabry disease | |
Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities. | |
Public Health Leadership in a VUCA World Environment: Lessons Learned during the Regional Emergency Rollout of SARS-CoV-2 Vaccinations in Heidelberg, Germany, during the COVID-19 Pandemic | |
Punctate calcifications in lysosomal storage disorders | |
Quantitative clinical characteristics of 53 patients with MPS VII: a cross-sectional analysis | |
Quantitative dysmorphology assessment in Fabry disease. | |
Quantitative retrospective natural history modeling of <i>WDR45</i>-related developmental and epileptic encephalopathy – a systematic cross-sectional analysis of 160 published cases | |
Randomized, controlled trial of miglustat in Gaucher's disease type 3. | |
The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women | |
The saccadic and neurological deficits in type 3 Gaucher disease | |
Screening for respiratory syncytial virus and isolation strategies in children hospitalized with acute respiratory tract infection | |
Skin-impedance in Fabry Disease: a prospective, controlled, non-randomized clinical study | |
Ten Years after the International Committee of Medical Journal Editors' Clinical Trial Registration Initiative, One Quarter of Phase 3 Pediatric Epilepsy Clinical Trials Still Remain Unpublished: A Cross Sectional Analysis | |
Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease | |
Thirty Years of Orphan Drug Legislation and the Development of Drugs to Treat Rare Seizure Conditions: A Cross Sectional Analysis | |
Towards Better Preparedness for Future Catastrophes Lessons Learned from Civil-Military Pandemic Response | |
Ultra-orphan lysosomal storage diseases: A cross-sectional quantitative analysis of the natural history of alpha-mannosidosis | |
Use of gabapentin to reduce chronic neuropathic pain in Fabry disease | |
Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. |